Skip to main content
      Phase 1 study of CAR-Treg in difficult to treat RA

      4/6 pts had 50% reduction in TJC/SJC, no CYC/fludrabine required &am

      Mike Putman EBRheum

      4 months ago
      Phase 1 study of CAR-Treg in difficult to treat RA 4/6 pts had 50% reduction in TJC/SJC, no CYC/fludrabine required & good prelim safety data CAR-T remains exciting, but less of the "totally magical everyone cured" stuff we saw w/initial CAR-T reports @RheumNow #ACR25 https://t.co/kjBIkLCYpF
      "Achieving good control of joint disease activity is probably the key objective of treatment of patients with RA-ILD"
      -

      Mike Putman EBRheum

      4 months ago
      "Achieving good control of joint disease activity is probably the key objective of treatment of patients with RA-ILD" - Gregory McDermott (Epi Abstracts, #2662) Totally agree with this! SARD guidelines recommendingn drugs with mediocre activity in RA was surprising @RheumNow
      Excited about this target trial emulation in RA-ILD

      Compared to RTX, NO significant difference in hospitalization/trans

      Mike Putman EBRheum

      4 months ago
      Excited about this target trial emulation in RA-ILD Compared to RTX, NO significant difference in hospitalization/transplant/death for JAK, ABA, IL6 or TNF Trends toward ABA and JAK looking better than RTX Need trials for sure, but I like this project a lot @RheumNow #ACR25 https://t.co/FQcphRvyHK
      In AxSpA, an 8-week personalized exercise program improved trunk strength (+14.1%), mobility (+14.9%), and cardiorespira

      Antoni Chan MD (Prof) synovialjoints

      4 months ago
      In AxSpA, an 8-week personalized exercise program improved trunk strength (+14.1%), mobility (+14.9%), and cardiorespiratory fitness ( increased oxygen pulse, ventilatory efficiency, anaerobic threshold). BASDAI and chest expansion also improved. Supports tailored rehab based on https://t.co/jawosa2AJK
      #Ianalumab decreases disease activity in active #Sjögren's #disease

      2 phase3 DB #RCT added to #SoC in primary #SjD
      &g

      Janet Pope Janetbirdope

      4 months ago
      #Ianalumab decreases disease activity in active #Sjögren's #disease 2 phase3 DB #RCT added to #SoC in primary #SjD >90% #Ro+ +#ESSDAI in monthly sc dosing vs placebo, Many 2ndary outcomes improved, safe LB#24 #ACR25 @ACRheum @RheumNow #ACRBest https://t.co/Z4ooUg7Nos
      In a PsA cohort (n=1291), higher BMI was independently linked to lower odds of achieving MDA—especially in TNFi-treate

      Antoni Chan MD (Prof) synovialjoints

      4 months ago
      In a PsA cohort (n=1291), higher BMI was independently linked to lower odds of achieving MDA—especially in TNFi-treated patients. Impact was strongest in pain, skin, enthesitis, and PRO domains, not swollen joints. Each unit increase in BMI reduced MDA odds by 4–7%. Highlights https://t.co/TxO3HP51uk
      #2686 Using HR-pQCT, researchers tracked bone changes in RA & PsA. Seropositive RA showed worst bone density & m

      Mrinalini Dey DrMiniDey

      4 months ago
      #2686 Using HR-pQCT, researchers tracked bone changes in RA & PsA. Seropositive RA showed worst bone density & microstructure, worsening with disease activity. TNFi, RTX & BARI improved MCP bone density, highlighting the impact of inflammation and treatment. @RheumNow #ACR25
      Will CAR-Treg Rx be helpful in active #refractory #rheumatoid #arthritis?

      Early data n=6 treated w low dose (3 per arm)

      Janet Pope Janetbirdope

      4 months ago
      Will CAR-Treg Rx be helpful in active #refractory #rheumatoid #arthritis? Early data n=6 treated w low dose (3 per arm), ongoing and doses will escalate Improvemt in #clinical #disease #activity less inflammation on #synovial #biopsies 3 pts #LB23 #ACR25 @RheumNow @ACRheum https://t.co/PkhsvztVjx
      GLP-1 RA vs DPP4i & risk of rheumatic disease: propensity score matched cohort study using TriNetX
      🔹 Lower incide

      Akhil Sood MD, MS AkhilSoodMD

      4 months ago
      GLP-1 RA vs DPP4i & risk of rheumatic disease: propensity score matched cohort study using TriNetX 🔹 Lower incidence of OA, RA & gout w/ GLP-1 RA 🔹 No significant differences for PsA, SSc, axSpA, or SLE @RheumNow #ACR25 https://t.co/BIVw3ajrFZ
      #2662
      Using Medicare data to emulate real-world RA-ILD trials, investigators compared RTX vs ABA, TOC, JAKi & TNFi
      N

      Mrinalini Dey DrMiniDey

      4 months ago
      #2662 Using Medicare data to emulate real-world RA-ILD trials, investigators compared RTX vs ABA, TOC, JAKi & TNFi No sig differences in mortality, resp, hospitalisation or lung transplant across groups, suggesting other b/tsDMARDs may be as safe as RTX for RAILD @RheumNow #ACR25
      Abstract 2694: Neutrophil:Lymphocyte ratio (NLR)- a practical step towards clinical monitoring of interferon?

      Log₂NL

      Akhil Sood MD, MS AkhilSoodMD

      4 months ago
      Abstract 2694: Neutrophil:Lymphocyte ratio (NLR)- a practical step towards clinical monitoring of interferon? Log₂NLR significantly correlated with all three IFN signatures across patients with SLE, systemic sclerosis, rheumatoid arthritis, and myositis @RheumNow #ACR25 https://t.co/ujaOQGvAUV
      ×